Wide Ranks

ALLR

Allarity Therapeutics, Inc.

1.11

Top Statistics
Market Cap 4 M Forward PE -0.0237 Revenue Growth 0.00 %
Current Ratio 2.01 Trailing PE 0.0002 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.9420 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 19 M Total Cash Per Share 13.62 Total Debt 1 M
Total Debt To Equity 6.68 Current Ratio 2.01 Book Value Per Share -15.26
All Measures
Short Ratio 30.00 % Message Board Id finmb_225998297 Shares Short Prior Month 141717
Return On Equity -1.22 City Boston Uuid 069341ee-08be-3463-988c-4bfe8cb84acd
Previous Close 1.24 First Trade Date Epoch Utc 1 B Book Value -15.26
Beta 0.2910 Total Debt 1 M Volume 385980
Last Split Date 1 B Fifty Two Week Low 1.10 Total Cash Per Share 13.62
Shares Short Previous Month Date 1 B Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -12823000 Short Percent Of Float 0.1270 Implied Shares Outstanding 4 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 296410
Average Volume10days 296410 Total Cash 19 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1232 Trailing PE 0.0002 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.24 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.59 Open 1.20
Free Cashflow -12938500 State MA Dividend Yield 0.00 %
Return On Assets -0.4772 Time Zone Short Name EST Trailing Eps 5449.42
Day Low 1.10 Address1 24 School Street Shares Outstanding 4 M
Price Hint 4 Target High Price 0.0000 Website https://www.allarity.com
52 Week Change -0.9967 Average Volume 604124 Forward Eps -46.92
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 196.00 %
Last Split Factor 1:30 Regular Market Day High 1.26 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 6.68 Fifty Two Week High 666.00
Day High 1.26 Shares Short 179436 Regular Market Open 1.20
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.1270 Operating Cashflow -15751000 Currency USD
Time Zone Full Name America/New_York Market Cap 4 M Is_nasdaq_100 False
Zip 02108 Quote Type EQUITY Industry Biotechnology
Long Name Allarity Therapeutics, Inc. Regular Market Day Low 1.10 Held Percent Institutions 0.0221
Current Price 1.11 Address2 2nd Floor Enterprise To Ebitda 0.9420
Financial Currency USD Current Ratio 2.01 Industry Disp Biotechnology
Country United States Float Shares 1 M Two Hundred Day Average 49.21
Enterprise Value -15916165 Forward PE -0.0237 Regular Market Volume 385980
Ebitda -16895000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.

Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty.

Ltd.

to develop Deflexifol for the treatment of solid tumors.

The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.